News & Views
Agilent and A*STAR's BTI Collaborate on New Bioanalytical Methodologies
Sep 09 2015
Agilent Technologies and the Bioprocessing Technology Institute (BTI), a research institute of Singapore’s Agency for Science, Technology and Research (A*STAR) announced that they will collaborate on new analytical approaches to analysing specific protein-linked sugar compounds. The collaboration will address a gap in analytical tests and standards applied for drugs based on glycoproteins, which now form the majority of approved biopharmaceutical drugs. Current analytical methods for characterising glycans are time-consuming and difficult to deploy in commercial environments. They are also limited in their ability to detect and analyse minor glycan species.
According to Nino Totino, General Manager for Agilent’s Life Sciences and Applied Markets Group in the South Asia, Pacific and Korea region, there is a critical need in the biopharmaceutical industry for a novel technology platform that can support detailed glycan analysis quickly and effectively in a high throughput environment. Both Agilent and BTI will work together on several projects that could lead to the creation of rigorous, standardised tests for drug safety and efficacy.
In this Edition Articles - Applications of Newly Developed 2.7 μm Porous Graphitic Carbon Particles in U/HPLC - Improve sensitivity and decrease matrix effects in pesticide residue analysis...
View all digital editions
Oct 31 2021 Philadelphia, PA, USA
Nov 02 2021 Johannesburg, South Africa
Nov 03 2021 Birmingham, UK
Nov 07 2021 Porto, Portugal
Nov 08 2021 Chiba, Japan